1. The use and therapeutic drug monitoring of teicoplanin in the UK
E.S.R. Darley 
Clinical Microbiology and Infection 
Volume 10, Issue 1, Pages (January 2004)
DOI: /j x
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

2. Fig. 1
Recommended daily teicoplanin dosage (mg/kg) for MRSA cellulitis. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide, once-daily.
Clinical Microbiology and Infection  , 62-69DOI: ( /j x)
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

3. Fig. 2
Desired pre-dose teicoplanin concentrations for MRSA cellulitis according to preferred glycopeptide. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide.
Clinical Microbiology and Infection  , 62-69DOI: ( /j x)
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

4. Fig. 3
Desired pre-dose teicoplanin concentrations for MRSA osteomyelitis according to preferred glycopeptide. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide.
Clinical Microbiology and Infection  , 62-69DOI: ( /j x)
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

5. Fig. 4
Desired pre-dose teicoplanin concentrations for MRSA bacteraemia according to preferred glycopeptide. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide.
Clinical Microbiology and Infection  , 62-69DOI: ( /j x)
Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions